Deerfield Management

School of Medicine Basic Sciences researchers at the forefront of Charcot-Marie-Tooth disease research and therapeutic development join CTTC leadership at CMT Research Foundation global research convention. The CMTRF has invested in further research at Vanderbilt to address the primary genetic cause of disease in patients with CMT disease type 1A. Read More

The CMT Research Foundation, a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease*, has invested in a project at Vanderbilt University School of Medicine Basic Sciences that seeks to treat the problem of overproduction of PMP22, the primary genetic cause of CMT in patients with CMT1A. Read More

Vanderbilt University leaders hosted visitors from the health care investment firm Deerfield Management on Feb. 23 for a series of events celebrating the ongoing collaboration between Vanderbilt and Deerfield to rapidly advance new therapeutics from the research bench to patients. Read More

Research in the Weaver lab leads to discoveries that help secure partnership with Ancora Innovation LLC.  “Vanderbilt is at the forefront of genetic research. By understanding the genetic causes of disease opens exciting new opportunities to develop drugs to treat them more effectively,” said Matt Nelson, vice president, genetics and genomics, 3DC at Deerfield Management.  Read More

Appello Pharmaceuticals Inc. begins trial of a drug candidate that improves relief from symptoms of Parkinson’s disease without debilitating side effects. Read More

The 17th annual Vanderbilt Institute of Chemical Biology Symposium, hosted by the Vanderbilt Institute of Chemical Biology and the Chemical Biology Association of Students, is scheduled for Thursday, Aug. 12, from 8:30 a.m. to 5:15 p.m. CT. The event is sponsored by Ancora Innovation, through Vanderbilt’s partnership with Deerfield Management, and will be broadcast remotely. Read More

Vanderbilt's partnership with Deerfield Management, Ancora, is opening a new request for applications focused on rare genetic diseases in January 2021. Faculty interested in this rolling submission-review opportunity are invited to attend an information session, "Accelerating the Commercialization of Transformative Biomedical Technologies with a Focus on Rare Genetic Diseases," on Thursday, Jan. 21, at 10 a.m. CT. Read More

Further research by biochemistry professors Charles Sanders and  Bruce Carter into therapeutics for Charcot-Marie-Tooth disease, an inherited condition that damages peripheral nerves, will be funded by Ancora Innovation LLC, a Deerfield Management company that supports Vanderbilt’s innovative life science research. Read More

The 16th annual Vanderbilt Institute of Chemical Biology Symposium is scheduled for Thursday, Aug. 6, from 8:30 a.m. to 5:15 p.m. CST. The event is sponsored by Ancora Innovation through Vanderbilt’s partnership with Deerfield Management and will be broadcast remotely. Read More

This is the second request for proposals to Ancora since Vanderbilt and Deerfield launched their collaboration in 2018 with a commitment from Deerfield of up to $65 million in initial funding over five years to support promising drug discovery research. Read More

Vanderbilt's Center for Technology Transfer and Commercialization, the Vanderbilt Institute of Chemical Biology and Deerfield will bring together experts in discovery and development of antibody therapeutics Jan. 23 to discuss and review state-of-the-art developments in the field. Read More

Vanderbilt's Center for Technology Transfer and Commercialization, the Vanderbilt Institute of Chemical Biology and Deerfield will bring together experts in discovery and development of antibody therapeutics Jan. 23 to discuss and review state-of-the-art developments in the field. Read More

Ancora Innovation, LLC, the new collaboration between Vanderbilt and Deerfield Management established earlier this year, has completed its inaugural proposal review process and announced two projects selected for funding. Read More

Appello was established with major investment from New York-based Deerfield Management, which specializes in accelerating drug development projects at universities and other nonprofits. Read More

The Office of the Vice Provost for Research and the Center for Technology Transfer and Commercialization have posted informational slides for faculty preparing pre-proposal submissions in response to the inaugural Ancora request for proposals. Read More

The Center for Technology Transfer and Commercialization's Alan Bentley will discuss emerging initiatives at Vanderbilt to engage industry more effectively, and a team from Deerfield Management will explain its collaborative approach to working with premier academic institutions to catalyze early stage therapeutic development. Read More

Deerfield Management and Vanderbilt University announced March 28 the launch of Ancora Innovation, LLC (“Ancora”), a Deerfield company that will support Vanderbilt’s innovative life science research and leverage Deerfield’s expertise in accelerating state-of-the-art drug development. Read More